Articles By Jack Cush, MD
ACR 2026 – Big Pharma Brings Its Biggest Readouts to Orlando
ACR Convergence 2026 runs November 6–11 in Orlando, and the major companies will be presenting their highlight trials this week. Phase 3 results in Sjögren's and gout headline the late-breaking orals, while plenaries feature a head-to-head PsA trial and lupus nephritis biopsy data.
Read Article
ACR 2026 – Biotech and Mid-Size Companies Bet on Novel Mechanisms
ACR Convergence 2026 is crowded with first-in-class mechanisms: an oral IL-23 receptor peptide, FcRn blockade, a JAK head-to-head and a wave of cell depletion therapies. Top abstracts include (all times ET):Argenx
Read Article
3 x IL-23 = IL do Better (11.6.2026)
Dr. Jack Cush reviews the FDA approvals and news reports from this past week on RheumNow.com. This week we discuss playing the numbers in rheumatology, playing the long game with stem cell transplants, and a=the Positive spin on seronegative RA.
Read Article
Autologous HCT in Severe Systemic Sclerosis
An international study reports 60% progression-free survival at 10 years after autologous bone marrow transplantation, adding important evidence on sustained positive clinical outcomes and long-term safety in patients treated for early severe systemic sclerosis.
Read Article
The Concern about Seronegative RA
A current review of seronegative RA (SNRA) by D’Onofrio, et al in npj Autoimmunity shows the diverse fate of seronegative RA - which can resolve, persist or become refractory. Clearly dedicated trials of SNRA are needed to better predict.
Read Article
FDA Approves Tildrakizumab for Psoriatic Arthritis
Sun Pharmaceuticals announced Friday that the FDA has approved its IL-23 inhibitor, tildrakizumab (Ilumya) for use in patients with active psoriatic arthritis.
Read Article
Mixed Drinks, Mixed Results (10.30.2026)
Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis.
Read Article
Beyond Chondrocalcinosis - What’s New in CPPD Disease
An overview of calcium pyrophosphate deposition (CPPD) disease by Sara Tedeschi presents our evolving understanding of CPPD with advances affecting nomenclature, classification, imaging, genetics, long-term outcomes and potential future targeted therapies. This review builds on other important reports on CPPD.
Read Article
The Efficacy of Ianalumab in Sjögren’s Disease
The NEPTUNUS-1 and NEPTUNUS-2 trials have showed that monthly ianalumab is superior of placebo at improving Sjögren’s disease activity at week 48, even though there was no significant ESSDAI response or in the change in SSSD or ESSPRI symptom scores.
Read Article
2026 BSR Guideline for the Treatment of Polymyalgia Rheumatica
Toyoda and colleagues from the British Society for Rheumatology have published new PMR treatment guidelines to supercede the previously published 2009 BSR/BHPR PMR guidelines. These guidelines emphasize earlier specialist input, methotrexate as an option, and bone protection for all PMR patients who will require chronic glucocorticoids.
Read Article